Resmed Q2 adjusted EPS beats estimates

ResMed

29/01/2026 21:14

Overview

Sleep device maker's Q2 revenue rose 11%, meeting analyst expectations

Adjusted EPS for Q2 beat analyst expectations

Company repurchased 704,000 shares for $175 mln

Outlook

Resmed plans to invest in innovation to scale digital health capabilities

Company aims for sustainable, profitable growth in the second half of fiscal 2026

Result Drivers

DEVICE DEMAND - Strong demand for sleep and respiratory care devices drove revenue growth

MARGIN IMPROVEMENT - Gross margin increased due to manufacturing and logistics efficiencies and component cost improvements

SG&A EXPENSES - SG&A expenses rose due to VirtuOx acquisition, employee costs, and marketing and technology investments

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Meet
$1.40 bln
$1.40 bln (16 Analysts)
Q2 Adjusted EPS
Beat
$2.81
$2.72 (15 Analysts)
Q2 EPS
$2.68
Q2 Adjusted Gross Margin
62.30%


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", 7 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for Resmed Inc is $299.00, about 16% above its January 28 closing price of $257.72

The stock recently traded at 22 times the next 12-month earnings vs. a P/E of 25 three months ago

Press Release: ID:nGNX6GVSKC

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)